Arbutus Biopharma Corporation (ABUS)
ABUS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$4.11
-0.96% on the day
Market cap
$630.0M
Small cap
Revenue · 2025
$14.1M
+128.2% on 2024
Net income · 2025
-$33.5M
-237.9% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | ABUS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001447028 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | A1 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $14.1M |
| Net income | -$33.5M |
| Operating income | -$38.2M |
| Net margin | -237.9% |
| Operating margin | -271.0% |
| Revenue growth | +128.2% |
| Cash | $18.0M |
| Total assets | $94.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 44.7× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2024-11-06 |
| Latest annual report | 10-K | 2026-03-23 |
| Latest quarterly / interim | 10-Q | 2026-08-12 |
| Latest current report FORM 8-K | 8-K | 2026-08-21 |
| Latest proxy | DEFA14A | 2026-04-14 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.3% |
| 1 month | -17.2% |
| 3 months | -11.6% |
| Year to date | -12.9% |
| 1 year | -2.1% |
| From 52-week high | -19.7% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| WVE | Wave Life Sciences Inc. | $3.14 | -4.27% | $618.7M |
| ZVRA | Zevra Therapeutics Inc. | $10.39 | -8.22% | $617.0M |
| AVTX | Avalo Therapeutics Inc. | $12.01 | -9.29% | $644.1M |
| OLMA | Olema Pharmaceuticals Inc. | $7.02 | -4.62% | $614.2M |
| DSGN | Design Therapeutics Inc. | $9.78 | -10.36% | $612.0M |
| PHAR | Pharming Group N.V. ADS each representing 10 | $9.44 | -1.77% | $666.7M |
| IRWD | Ironwood Pharmaceuticals Inc. | $3.59 | -4.52% | $593.2M |
| CLYM | Climb Bio Inc. | $10.31 | -4.80% | $592.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier